



Hyperoxia-induced lung structure-function relation, vessel rarefaction, and cardiac hypertrophy in an infant rat model

Greco, Francesco ; Wiegert, Susanne ; Baumann, Philipp ; Wellmann, Sven ; Pellegrini, Giovanni ; Cannizzaro, Vincenzo

Abstract: **BACKGROUND** Hyperoxia-induced bronchopulmonary dysplasia (BPD) models are essential for better understanding and impacting on long-term pulmonary, cardiovascular, and neurological sequelae of this chronic disease. Only few experimental studies have systematically compared structural alterations with lung function measurements. **METHODS** In three separate and consecutive series, Sprague-Dawley infant rats were exposed from day of life (DOL) 1 to 19 to either room air (0.21; controls) or to fractions of inspired oxygen (FiO) of 0.6, 0.8, and 1.0. Our primary outcome parameters were histopathologic analyses of heart, lungs, and respiratory system mechanics, assessed via image analysis tools and the forced oscillation technique, respectively. **RESULTS** Exposure to FiO of 0.8 and 1.0 resulted in significantly lower body weights and elevated coefficients of lung tissue damping (G) and elastance (H) when compared with controls. Hysteresivity () was lower due to a more pronounced increase of H when compared with G. A positive structure-function relation was demonstrated between H and the lung parenchymal content of α -smooth muscle actin (α -SMA) under hyperoxic conditions. Moreover, histology and morphometric analyses revealed alveolar simplification, fewer pulmonary arterioles, increased α -SMA content in pulmonary vessels, and right heart hypertrophy following hyperoxia. Also, in comparison to controls, hyperoxia resulted in significantly lower plasma levels of vascular endothelial growth factor (VEGF). Lastly, rats in hyperoxia showed hyperactive and a more explorative behaviour. **CONCLUSIONS** Our in vivo infant rat model mimics clinical key features of BPD. To the best of our knowledge, this is the first BPD rat model demonstrating an association between lung structure and function. Moreover, we provide additional evidence that infant rats subjected to hyperoxia develop rarefaction of pulmonary vessels, augmented vascular α -SMA, and adaptive cardiac hypertrophy. Thus, our model provides a clinically relevant tool to further investigate diseases related to O toxicity and to evaluate novel pharmacological treatment strategies.

DOI: <https://doi.org/10.1186/s12967-019-1843-1>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-169955>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

Greco, Francesco; Wiegert, Susanne; Baumann, Philipp; Wellmann, Sven; Pellegrini, Giovanni; Cannizzaro, Vincenzo (2019). Hyperoxia-induced lung structure-function relation, vessel rarefaction, and cardiac hypertrophy in an infant rat model. *Journal of Translational Medicine*, 17:91.


DOI: <https://doi.org/10.1186/s12967-019-1843-1>

RESEARCH

Open Access



Hyperoxia-induced lung structure–function relation, vessel rarefaction, and cardiac hypertrophy in an infant rat model

Francesco Greco^{1,2,3}, Susanne Wiegert^{1,2,3}, Philipp Baumann^{1,2}, Sven Wellmann⁴, Giovanni Pellegrini^{5,6} and Vincenzo Cannizzaro^{1,2,3*} 

Abstract

Background: Hyperoxia-induced bronchopulmonary dysplasia (BPD) models are essential for better understanding and impacting on long-term pulmonary, cardiovascular, and neurological sequelae of this chronic disease. Only few experimental studies have systematically compared structural alterations with lung function measurements.

Methods: In three separate and consecutive series, Sprague–Dawley infant rats were exposed from day of life (DOL) 1 to 19 to either room air (0.21; controls) or to fractions of inspired oxygen (FiO₂) of 0.6, 0.8, and 1.0. Our primary outcome parameters were histopathologic analyses of heart, lungs, and respiratory system mechanics, assessed via image analysis tools and the forced oscillation technique, respectively.

Results: Exposure to FiO₂ of 0.8 and 1.0 resulted in significantly lower body weights and elevated coefficients of lung tissue damping (G) and elastance (H) when compared with controls. Hysteresivity (η) was lower due to a more pronounced increase of H when compared with G. A positive structure–function relation was demonstrated between H and the lung parenchymal content of α -smooth muscle actin (α -SMA) under hyperoxic conditions. Moreover, histology and morphometric analyses revealed alveolar simplification, fewer pulmonary arterioles, increased α -SMA content in pulmonary vessels, and right heart hypertrophy following hyperoxia. Also, in comparison to controls, hyperoxia resulted in significantly lower plasma levels of vascular endothelial growth factor (VEGF). Lastly, rats in hyperoxia showed hyperactive and a more explorative behaviour.

Conclusions: Our in vivo infant rat model mimics clinical key features of BPD. To the best of our knowledge, this is the first BPD rat model demonstrating an association between lung structure and function. Moreover, we provide additional evidence that infant rats subjected to hyperoxia develop rarefaction of pulmonary vessels, augmented vascular α -SMA, and adaptive cardiac hypertrophy. Thus, our model provides a clinically relevant tool to further investigate diseases related to O₂ toxicity and to evaluate novel pharmacological treatment strategies.

Keywords: Hyperoxia, Bronchopulmonary dysplasia, Animal model, Respiratory system mechanics, Forced oscillation technique, Hysteresivity η , α -Smooth muscle actin (α -SMA), Vascular endothelial growth factor (VEGF), Digital pathology

*Correspondence: vincenzo.cannizzaro@kispi.uzh.ch

¹ Department of Intensive Care Medicine and Neonatology, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland
Full list of author information is available at the end of the article



Background

Administration of supplemental oxygen (O_2) is a cornerstone in the treatment of hypoxaemic critically ill infants and children. In fact, hypoxaemia is a dangerous condition that might end in persistent organ damage and neurological sequelae. While hypoxaemia is feared and well known, noxious effects of excessive O_2 therapy are generally less recognised [1]. Neonatologists are familiar with clinical consequences of disproportionate O_2 administration and challenged by bronchopulmonary dysplasia (BPD), a multifactorial chronic lung disease that mainly occurs in premature infants requiring mechanical ventilation and O_2 therapy [2]. Moreover, BPD is strongly associated with non-favourable long-term cardiovascular and neurological disorders [3–6]. In contrast, paediatric and adult intensivists maintain a rather liberal attitude towards O_2 therapy despite increasing evidence of harmful systemic effects of hyperoxia in nonhypoxaemic critically ill patients [7]. The current liberal practice is concerning since hyperoxia leads to non-physiologic states favouring oxidative stress [8].

Although experimental BPD models allowed invasive studies that cannot be performed in nonhypoxaemic humans, their translational potential has not been fully explored. Over the last decade, researchers established a variety of animal models to study a broad range of O_2 concentrations applied over several days. Rats seem to be well suited to model developmental changes encountered in human lungs [9–11]. In particular, infant rat models of hyperoxia closely mimic histological features of the disorganised lung architecture observed in human BPD [12]. Other advantages of using rats include their highly developed social behaviour and relatively large body size, which makes it easier to carry out behavioural experiments, sampling, and surgical manipulations, respectively. In addition, small animal models continue to provide a platform for testing both established and novel treatment strategies for children affected from chronic pulmonary and cardiovascular disease [13, 14].

Despite the above mentioned advantages of hyperoxia-based infant rat models, we argue that their potential has not been maximised, yet. First, besides alveolar simplification, lung fibrosis, and pulmonary vascular remodelling, BPD comes clinically along with impaired respiratory function. However, only few experimental studies have systematically compared structural alterations with sophisticated lung function measurements [15]. Second, traditional histopathologic analyses are prone to less standardised and randomised collection and interpretation of data, particularly when compared to the advantages of image analysis. Third, there is a lack of animal models focusing on extra-pulmonary sequelae of hyperoxia-induced tissue damage.

Hence, the primary aim of our study was to relate alveolar remodelling and fibrosis with respiratory function assessed via image analysis tools and the forced oscillation technique, respectively. We hypothesised an association between these structural alterations and respiratory system mechanics. The second hypothesis was that long-term hyperoxia results in rarefaction of pulmonary vessels, augmented vascular α -SMA, and adaptive cardiac hypertrophy.

Methods

Animals

Pregnant Sprague Dawley (SD) dams were purchased from Charles Rivers Laboratories International, Inc. (Sulzfeld, Germany) and delivered on day 14 of pregnancy (E14). Since the average length of the gestation period in rats varies between 21 and 23 days (E21–E23), pregnant dams had at least 1 week of acclimatization, in order to reduce the stress associated with transportation, before the initiation of our experiments. Dams and their pups born in our laboratory facility on day of life (DOL) 0 were housed in individual sealed cages (T1500 IVC) under 12 h light and dark cycle with ad libitum access to water and food, at temperatures of 22–24 °C, and humidity of 30–60%. The litter size varied from 8 to 15 rat pups.

From DOL 1 to 19, dams and their pups were exposed in three separate and consecutive series to room air (0.21), and to a fraction of inspired oxygen (FiO_2) of 0.6, 0.8, and 1.0. The hyperoxic environment was created by a computer-controlled O_2 system based on the software IOX (EMKA Technologies, Paris, France). Carbon dioxide (CO_2) concentrations in the cages were targeted to be below 0.4% and controlled using gas flows of 3–5 Standard Liter Per Minute. Flow rates in the normoxic cages were regulated accordingly via flow regulator Vent2 (EMKA Technologies, Paris, France). O_2 and CO_2 concentrations were monitored three times per day using the O_2 and CO_2 Datex-Ohmeda sensor (Anandic Medical System, Switzerland). As adult rats do not tolerate chronic exposure of high O_2 levels, dams were rotated every 24 h between hyperoxic and room air conditions to prevent hyperoxia-associated stress and discomfort. The chambers were daily opened for 10 min to switch the dams, weigh the pups, and clean the cages.

Well-being and social interaction were assessed three times daily and all findings were recorded on a standardised score sheet. Except for daily health checks via observation of hunched posture, piloerection, eye discharge, and reduced social interaction, dams and pups did not experience any physical manipulation until DOL 5, when each pup was tattooed on toes according to the universal rodent numbering system. Tattoos were performed by pricking the skin of a specific finger with a needle dipped

in ink (Aramis Laboratory Animal Microtattoo System, Ketchum Manufacturing, Brockville, Canada).

The method of sacrifice of the infant rats at the end of all experiments was maximum blood withdrawal via direct cardiac puncture in a separate room. After euthanasia of all pups, dams were culled in a euthanasia chamber via CO₂ gas exposure.

Respiratory system mechanics

On DOL 19, after brief inhalational anaesthesia with isoflurane, infant rats were anaesthetised with an intraperitoneal injection of a solution containing 75 µg/g body weight (BW) of ketamine and 10 µg/g BW of xylazine. After weighing each animal and confirmation of adequate level of anaesthesia via absence of pedal withdrawal reflex, a tracheostomy was performed and a 10 mm polyethylene cannula (ID: 0.86 mm) was inserted. Rats were then placed in supine position on a heating mat and connected to a computer-controlled ventilator (flexiVent®, Scireq, Montreal, Canada) using the following settings: fraction of inspired O₂ (FiO₂) 0.4 and 1.0 for the normoxic and hyperoxic group, respectively, respiratory rate (RR) 90/min, tidal volume (V_T) of 8 mL/kg, and positive end-expiratory pressure (PEEP) 5 cm H₂O. PEEP was regulated by submerging the end of the expiratory tube into a water column. In addition, heart rate, blood pressure, and O₂ saturation (SpO₂) were monitored with a small animal pulse oximeter (MouseOx™, STARR Life Sciences Corporation™, Oakmont, PA, USA) by placing a sensor on the proximal part of the thigh.

Next, lung volume history was standardised within 5 min by two lung volume recruitment manoeuvres from 5 cm H₂O to 40 cm H₂O with 9 s ramp and 3 s plateau. Then, baseline measurement of respiratory system input impedance (Z_{rs}) was performed using the low-frequency forced oscillation technique (FOT) provided by the flexiVent® system. Z_{rs} was obtained with a 6 s oscillation signal of 17 mutually prime frequencies from 0.5 to 19.75 Hz applied to the airway of the infant rat with a PEEP of 5 cm H₂O to prevent lung derecruitment during Z_{rs} measurements. Thus, oscillations were delivered on top of these PEEP levels. The “constant-phase” model was then fitted to the resulting Z_{rs}, allowing the estimation of airway resistance (R_{aw}), and the coefficients of tissue damping (G) and elastance (H). Values of R_{aw} were corrected for the resistance of the tracheal cannula. Lung tissue hysteresivity (η) was calculated as the ratio of G and H. After lung function assessments pups underwent terminal blood withdrawal and tissue sampling. Infant rats exposed to FiO₂ 0.6 did not undergo assessment of respiratory system mechanics due to lack of differences in weight and social behaviour when compared to the normoxic group.

Sampling and processing of blood

Before disconnecting animals from the ventilator, partial laparotomy and sternotomy were performed and blood was taken via direct cardiac puncture. Blood was collected in plastic tubes containing the anticoagulant EDTA and kept on ice before centrifugation at 3000 rpm for 10 min. Plasma was frozen at −80 °C for further analysis of endothelin-1 (ET-1), and vascular endothelial growth factor (VEGF) via fluorescence immunoassays. Since VEGF is a marker of impaired vascular development, we did not measure its concentration in the series of experiments using FiO₂ 0.6 and 0.8 where pulmonary vessels were not analysed histologically.

Sampling and processing of lung and heart tissues

Lungs of infant rats exposed to FiO₂ 1.0 were inflated and fixed via tracheal instillation of 4% formalin with a pressure of 10 cm H₂O. Thirty minutes later, lungs and heart were removed en bloc from the thoracic cavity and stored at −4 °C in a formalin filled container until histological processing. After fixation for 48 h, lungs and heart were trimmed, dehydrated through graded alcohols and routinely paraffin wax embedded. Consecutive sections (3–5 µm) were prepared, mounted on glass slides and routinely stained with haematoxylin and eosin (H&E), Gomori blue trichrome or subjected to immunohistochemical staining for the detection of smooth muscle and endothelial cells. Briefly, sections were incubated with antibodies against α-SMA (anti-human alpha-smooth muscle actin mouse monoclonal antibody), and von Willebrand Factor (anti-human factor VIII-related antigen (FVIII-Rag) rabbit polyclonal antibody, A0082, Dako-Agilent Technologies, Denmark; 1:100) for 1 h at 37 °C. Afterwards, the slides were incubated for 30 min with a horse radish peroxidase (HRP)-labelled polymer, conjugated to a secondary anti-mouse and anti-rabbit antibody (Dako Envision™ System, Dako-Agilent Technologies), respectively. The reaction was visualised using 3,3'-diaminobenzidine (DAB) as chromogen, followed by light counterstain with haematoxylin. The immunohistochemical staining was performed using an Autostainer (Dako Autostainer Universal Staining System Model LV-1, Dako-Agilent Technologies). In addition, heart sections were stained with a fluorescent wheat germ agglutinin to assess cardiomyocyte size. All slides were scanned using a digital slide scanner (NanoZoomer-XR C12000; Hamamatsu, Japan) and histomorphometrical analysis was performed on the digital slides using the Visiopharm Integrator System (VIS, version 4.5.1.324, Visiopharm, Hørsholm, Denmark), unless specified otherwise.

Lung fibrosis

Myofibroblasts, key effector cells in the development of fibrosis, were identified in lung sections immunostained for anti- α -SMA. α -SMA-positive areas were quantified in each animal using at least 15 fields per section. Results were expressed as fraction of α -SMA-positive areas normalised against the total lung parenchyma excluding the airspace.

Histomorphometrical study of alveolar remodelling

Alveolar diameters were estimated calculating the mean linear intercept (chord) length (Lm), equal to the mean interalveolar distance, as described previously [16]. In each animal, 10 representative pictures were taken at 40 \times magnification from the H&E-stained lung sections, avoiding regions with large bronchi. A grid with 11 parallel lines was overlaid onto each image, and the length of each chord was defined by the intercept with the alveolar walls. Mean Lm was calculated by dividing the total length of the line drawn across the lung section by the number of intercepts encountered.

Alveolar counts were determined via Visiopharm software by counting the number of alveoli per field in the H&E-stained sections. In each animal 15 fields per section were analysed at 40 \times magnification. Briefly, 15 regions of interest (ROIs) with a size of 0.298 mm² were randomly selected from the lung parenchyma in each animal. A threshold classification allowed to distinguish between alveolar lumina and alveolar wall, and to calculate the alveolar count in each ROI.

Pulmonary arterial medial wall thickness and count of pulmonary vessels

Pulmonary arterial medial wall hypertrophy was assessed at 40 \times magnification in lung sections immunostained for anti- α -SMA. At least 15 ROIs with a size of 2.605 mm², containing vessels with a diameter of <100 μ m, were randomly selected across the lung parenchyma of all animals, excluding fields containing terminal bronchioles. A threshold classification allowed to distinguish between α -SMA-positive and negative tissue. The results were expressed as α -SMA-positive area per cross sectional vessel. The number of pulmonary vessels was assessed in lung sections immunostained for von Willebrand Factor within the outlined ROIs. A threshold classification allowed to select vessels with a diameter between 30 and 100 μ m. Fields containing bronchioles were excluded from the analysis.

Right ventricular hypertrophy (RVH)

The thickness of the right (RV) and left (LV) ventricular free walls was measured in H&E-stained heart sections using the NDP view software (Hamamatsu Photonics),

and the RV/LV ratio was calculated as a marker of RVH. As an additional marker of RVH, the cross-sectional area of cardiomyocytes was assessed at 40 \times magnification in heart sections stained for anti-WGA (wheat germ agglutinin). A threshold classification allowed the recognition of WGA-stained membrane and empty sarcoplasm in at least 40 representative right ventricular cardiomyocytes with a central 4',6-diamidino-2-phenylindole (DAPI)-stained nucleus.

Statistical analysis

Statistical comparisons between the normoxic and hyperoxic group were performed using the t-test. Where satisfaction of normality and equality was not possible the non-parametric Mann–Whitney rank sum test was used. Values are reported as mean \pm standard deviation for body weight, and as mean \pm standard error of means for all other experimental data. Linear regression was used to examine the association between histological parameters and lung function. The strength of association was expressed as a coefficient of determination, denoted as r^2 . Statistically significant data are additionally expressed as vertical box plots with median, 10th, 25th, 75th, and 90th percentiles. Statistical significance was set at a p-value (p) < 0.05.

Results

Social behaviour, well-being, and survival rates


No signs of stress or abnormal behaviour were observed after exposure to FiO₂ 0.6 and 0.8. In contrast, all infant rats exposed to FiO₂ 1.0 developed a hyperactive behaviour from DOL 15 onwards. This behaviour was characterised by a pronounced exploration and interaction without signs of self-inflicted injuries or aggression towards littermates. There were no deaths.

Postnatal growth

Exposure to FiO₂ 0.6 did not affect weight gain in the hyperoxic group compared to normoxic controls (p = 0.645). In contrast, application of FiO₂ 0.8 resulted in a significant weight difference on DOL 19 with normoxic (n = 15) and hyperoxic (n = 14) animals weighing 39.1 ± 8 g and 36.1 ± 8 g, respectively (p = 0.041). A higher difference in weight was found in the FiO₂ 1.0 series with normoxic (n = 8) and hyperoxic (n = 8) infant rats weighing 42.9 ± 1.9 g and 38.0 ± 3.1 g, respectively (p < 0.001) (Fig. 1).

Respiratory system mechanics

A significantly higher airway resistance R_{aw} was found in rats exposed to FiO₂ 0.8 when compared to the control group (0.10 ± 0.01 cm H₂O s/mL versus 0.06 ± 0.01 cm H₂O s/mL) (p = 0.002). In contrast, exposure to FiO₂



1.0 resulted in significantly lower R_{aw} (0.09 ± 0.01 cm H_2O s/mL) in comparison with the normoxic group (0.15 ± 0.01 cm H_2O s/mL) ($p < 0.001$) (Fig. 2).

The coefficient of tissue damping G significantly increased by 38% and 21% in FiO_2 0.8 and 1.0, respectively, when compared to the respective normoxic groups (in both cases $p < 0.001$) (Fig. 2). A similar pattern was found for the coefficient of tissue elastance H , where FiO_2 0.8 and 1.0 resulted in 64% and 30% higher H , respectively, when compared to the control groups (in both cases $p < 0.001$) (Fig. 2). Lung tissue hysteresivity η was 18% and 7% lower after exposure to FiO_2 0.8 ($p = 0.021$) and 1.0 ($p = 0.132$), respectively, in comparison with the groups in normoxia.

Histology

Lung histology and morphometric analysis

In comparison with control animals held at room air (Fig. 3a), lung histology of rats exposed to FiO_2 1.0 was characterised by alveolar simplification, with fewer and larger alveoli (Fig. 3b). In particular, the hyperoxic group showed a significantly lower alveolar count per field (67 ± 3 vs 95 ± 3 , $p < 0.001$) (Fig. 3c) and higher mean alveolar intercept (84 ± 4 vs 52 ± 1 μm , $p < 0.001$) (Fig. 3d). On the contrary, no significant differences in lung α -SMA content were found between normoxia (0.029 ± 0.006) and hyperoxia (0.041 ± 0.003) ($p = 0.234$) (Fig. 3e).

Histology of pulmonary vessels and heart

Hyperoxia led to a significantly lower count of pulmonary arterioles per field (3.5 ± 0.2) in comparison with the normoxic group (5.9 ± 0.3) ($p < 0.001$) (Fig. 4a). In addition, we observed a significant difference in the hyperoxic group, when compared to normoxic controls, with regard

to α -SMA content in the medial wall of pulmonary vessels (1099 ± 46 versus 904 ± 50 μm^2 , $p = 0.013$) (Fig. 4b), RV/LV ratio (0.59 ± 0.05 versus 0.35 ± 0.01 , $p = 0.001$) (Fig. 4c), and cross-sectional area of the right ventricular cardiomyocytes (78.9 ± 3.0 μm^2 vs 55.3 ± 2.9 μm^2 , $p < 0.001$) (Fig. 4d).

Structure–function relation

A significant association between the content of α -SMA in lung parenchyma and tissue elastance H was observed in the hyperoxic study group ($r^2 = 0.753$, $p = 0.025$) (Fig. 5a). No association was found between mean linear intercept (L_m) and H , in both normoxia ($p = 0.414$) and hyperoxia ($p = 0.268$) (Fig. 5b).

Biomarkers


Biomarkers were measured at a single time point of DOL 19.

VEGF and ET-1 plasma concentrations

Hyperoxia resulted in significantly lower plasma levels of VEGF (3.7 ± 0.3 pg/mL) in comparison with the normoxic group (4.8 ± 0.1 pg/mL) ($p = 0.006$), (Fig. 6a). No significant differences in ET-1 concentration were found between normoxia (24.5 ± 1.8 pg/mL) and hyperoxia (21.4 ± 2.6 pg/mL) ($p = 0.417$) (Fig. 6b).

Discussion


This study provides an infant rat model of hyperoxia-induced tissue damage mimicking clinical key features of BPD. In line with our first hypothesis and as far as we know, this is the first BPD rat model demonstrating an association between lung structure and function using accurate diagnostic tools such as image analysis and FOT, respectively. Moreover, according to our second



hypothesis, we reproduced pronounced rarefaction of pulmonary vessels, augmented vascular α -SMA, and adaptive cardiac hypertrophy.

Rats have a high translational value because they are born at a lung developmental stage (saccular stage) equivalent to that of an extreme premature infant and reliably reproduce structural changes closely mimicking

human BPD [11, 12]. However, in our view the potential of BPD models has not been maximised, yet. In fact, although O_2 is the most commonly applied injurious stimulus for inducing pulmonary hallmark features of BPD [9], the use of different O_2 concentrations and time of exposure to reproduce key features of this disease has generated data difficult to compare [15].



Hence, our group first designed an O₂-response study consisting of three separate and consecutive series where infant rats were exposed to FiO₂ of 0.6, 0.8, and 1.0. FiO₂ 0.6 was insufficient to induce clinically relevant morbidity. On the contrary, the treatment with FiO₂ 1.0 resulted in earlier and more pronounced lower body weights than FiO₂ 0.8 as well as abnormal behaviour, in line with behavioural mice studies [17], when compared to normoxic controls.

The properties of the respiratory system mechanics were characterised via FOT. The high R_{aw} after exposure to FiO₂ 0.8 (Fig. 2a) was in line with previous studies where hyperoxia led to remodelling of conducting airways and smooth muscles, and to increased airway hyperresponsiveness in infant and adult rodents [9, 18, 19]. Surprisingly, exposure to FiO₂ 1.0 resulted in lower R_{aw} compared to normoxic controls (Fig. 2d). Since we did not assess structural changes of the airways, we can only speculate whether stress-related glucocorticoid and catecholamine release [20], though not perceivable by the experimenter, resulted in bronchodilation

outweighing remodelling of the airways. On the other hand, a study performed in a BPD rabbit model showed no significant differences in R_{aw} between normoxic and hyperoxic animals questioning the airway remodelling hypothesis [21].

In agreement with comparable experimental studies [21, 22], tissue damping G and tissue elastance H showed significantly higher values after exposure to hyperoxia (Fig. 2). Since G and H exhibit inverse dependencies on body weight [23], we supposed that higher G and H after application of FiO₂ 0.8 result from combined effects of hyperoxia and lower body weights. While G is closely related to tissue resistance and regional heterogeneity [24], common findings in BPD [2], H reflects tissue stiffness and reduced compliance [25]. Although the levels of α -SMA were not significantly increased in hyperoxia, we observed a ~40% higher concentration of this biomarker in hyperoxic animals (Fig. 3e). The accumulation of α -SMA in lung tissue reflects the differentiation of lung fibroblasts into myofibroblasts [26], which play a major role in the pathogenesis of pulmonary fibrosis [27].




Fig. 4 Histomorphometry of pulmonary vessels and heart. Normoxic and hyperoxic study groups are illustrated with white and grey box plots, respectively. **a–d** Count of pulmonary vessels ($n = 8 + 8$), α -SMA content in the medial wall of the pulmonary arterioles ($n = 7 + 8$), right-to-left ventricle wall thickness ratio ($n = 3 + 6$), cardiomyocyte cross-sectional area ($n = 7 + 8$) in normoxia and hyperoxia, respectively. Data are expressed as vertical box plots with median, 10th, 25th, 75th, and 90th percentiles. Asterisk displays a significant difference between study groups, $p < 0.05$

Lung tissue hysteresivity (η) is defined as the energy dissipated (G) relative to the elastic energy stored in the lung (H) [28]. In case of moderate to severe heterogeneity, G increases proportionally more than H [29–31]. In contrast, lung derecruitment comes along with a proportionate increase of G and H [31, 32]. Hence, η will rise or remain unchanged. In our study, a more pronounced increase of H in respect to G led to a decrease of η both after exposure to FiO_2 0.8 and FiO_2 1.0 (Fig. 2). This finding was unexpected. In theory, a fall in η can occur when H rises proportionally more than G or when H decreases to a lesser extent compared to G . The second scenario can be excluded, since we did neither observe lower values of H nor G in hyperoxia. Hence, in our view, the behaviour of η predominantly reflected progressive lung

volume derecruitment accompanied by a consecutive lung heterogeneity questioning the association between stable η and substantial derecruitment [31, 32].

Studies exploring the relationship between alterations in lung structure and functional impairment of respiratory mechanics in animal models of BPD are lacking [15]. Therefore, we related our histopathologic findings to changes in respiratory system mechanics. In contrast to experimental studies in emphysema rodent models [33, 34], our linear regression analysis did not show an association between L_m , the most commonly used index of airspace enlargement, and H (Fig. 5b). In our view, this finding is not surprising since BPD, as opposed to emphysema, cannot be considered solely an obstructive lung disease. In fact and consistent with the behaviour of




Fig. 5 Scatter plot of α -SMA to lung tissue ratio (a) and mean linear intercept (b) against lung tissue elastance (H). White and grey circles indicate the normoxic (n = 7) and FiO₂ 1.0 (n = 6) groups, respectively; r^2 = coefficient of determination




Fig. 6 VEGF and ET-1 concentrations in plasma. Normoxic and hyperoxic study groups are illustrated with white and grey box plots, respectively. **a** VEGF concentration in normoxia (n = 8) and hyperoxia (FiO₂ 1.0) (n = 8). **b** ET-1 concentration in normoxia (n = 8) and hyperoxia (n = 7). Data are expressed as vertical box plots with median, 10th, 25th, 75th, and 90th percentiles. Asterisk displays a significant change between study groups, $p < 0.05$

η , a linear relationship was detected between lung parenchymal α -SMA content and H (Fig. 5a), mirroring both loss of lung volume and a significant restrictive component in BPD.

In accordance with former rat BPD studies [35], we also found a significant rarefaction of pulmonary vessels (Fig. 4a) and higher concentration of α -SMA in smooth muscle cells of the pulmonary arteriolar wall (Fig. 4b). Significantly higher levels of the right-to-left ventricle diameter ratio (Fig. 4c) and cardiomyocyte cross-sectional area (Fig. 4d), both markers of RVH, can

be interpreted as a consequence of pulmonary vascular structural alterations leading to increased afterload, a common complication of BPD [6].

In agreement with comparable human BPD and animal studies [36, 37], we found that exposure to FiO₂ 1.0 led to a significantly lower VEGF concentration in plasma (Fig. 6a). Measurement of the second biomarker ET-1, involved in the pathogenesis of pulmonary vascular disease [38], did not differ between hyperoxic and control groups (Fig. 6b). Baumann et al. [39] found a significant difference in a precursor of ET-1 in BPD-affected

children until 28 days of age only. However, this difference vanished at 36 weeks postmenstrual age. From a translational point of view, 19 days old infant rats can be compared to preschool children. Hence, it is not surprising that at the time where we measured ET-1 no significant differences between study groups were observed.

This study is subject to limitations. First, although we inferred lung volume derecruitment from H values, we did not perform direct lung volume measurements. Second, we assumed that glucocorticoids and catecholamines were released by the neuroendocrine system to contrast stress. However, we neither assessed the concentration of stress hormones nor the airway calibre. Third, we did not perform standardised observational tests. In fact, our well-being score sheet was not designed to adequately capture hyperactive and explorative behaviour. Last, although O₂ represents the most commonly applied injurious trigger for inducing key features of BPD, it has to be taken into account that the etiology of BPD is multifactorial. Therefore, to truly mirror the multifactorial clinical and genetic conditions contributing to human BPD, an ideal animal model would aim at combining multiple factors [9]. This remains a substantial limitation, which can only partially be overcome by optimizing study methods.

Conclusions

To our knowledge, this is the first BPD rat model demonstrating an association between pulmonary structural and functional changes using accurate diagnostic tools such as image analysis and FOT, respectively. Moreover, we provide additional evidence that infant rats subjected to hyperoxia develop rarefaction of pulmonary vessels, augmented vascular α -SMA, and adaptive cardiac hypertrophy. Hence, the present in vivo study provides a clinically relevant model to further investigate pathogenesis of diseases related to O₂ toxicity and to evaluate novel pharmacological treatment strategies (Additional file 1: Figure S1).

Additional file

Additional file 1: Figure S1. ET-1 concentration in plasma. Normoxic and hyperoxic study groups are illustrated with white and grey box plots, respectively. **A:** ET-1 concentration in the normoxic (n = 13) and FiO₂ 0.6 groups (n = 14). **B:** ET-1 concentration in normoxia (n = 15) and hyperoxia (FiO₂ 0.8) (n = 14). Data are expressed as vertical box plots with median, 10th, 25th, 75th, and 90th percentiles.

Abbreviations

α -SMA: alpha-smooth muscle actin; BPD: bronchopulmonary dysplasia; BW: body weight; DOL: day of life; ET-1: endothelin-1; Eta (η): tissue hysteresivity; FiO₂: fraction of inspired oxygen; FOT: forced oscillation technique; G: tissue damping; H: tissue elastance; HIF-2: hypoxia-inducible factor-2; Lm: mean

linear intercept length; LV: left ventricle; n: number of animals; PEEP: positive end-expiratory pressure; R_{aw}: airway resistance; ROI: region of interest; RR: respiratory rate; RV: right ventricle; RVH: right ventricular hypertrophy; SD: Sprague–Dawley; VEGF: vascular endothelial growth factor; V_T: tidal volume; Z_{rs}: respiratory system impedance.

Authors' contributions

VC and FG conceived and designed experiments. FG and SW¹ performed animal experiments. FG and GP performed histological analyses. VC, FG, SW¹, PB, GP and SW² interpreted results of the animal experiments. VC and FG drafted the manuscript. VC, FG, SW¹, PB, GP and SW² edited and revised the manuscript. All experiments took place at the Animal Research Facility of the University Children's Hospital Zurich, Switzerland. ¹ Susanne Wiegert. ² Sven Wellmann. All authors read and approved the final manuscript

Author details

¹ Department of Intensive Care Medicine and Neonatology, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. ² Children's Research Centre, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. ³ Zurich Centre for Integrative Human Physiology, Zurich, Switzerland. ⁴ Department of Neonatology, University Children's Hospital Basel, Spitalstrasse 33, 4056 Basel, Switzerland. ⁵ Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty University of Zurich, Winterthurerstrasse 268, 8057 Zurich, Switzerland. ⁶ Present Address: Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.

Acknowledgements

The authors gratefully thank the team of the Institute of Veterinary Pathology of Zurich for preparing the histology slides and providing technical assistance during the histomorphometric analyses.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The research protocol, approved by the Cantonal Veterinary Office of Zurich (licence number 95/2014), was conducted according to the Ethical Principles and Guidelines for Experiments on Animals of the Swiss Academy of Medical Sciences and the Swiss Academy of Sciences.

Funding

This work was supported by a project grant by the Zurich Center for Integrative Human Physiology (ZIHP), and the Heartbay Foundation (Vaduz). No grant numbers are provided.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 18 December 2018 Accepted: 11 March 2019

Published online: 18 March 2019

References

- Ridder N, Plumb J, Grocott M. Oxygen therapy in critical illness: friend or foe? A review of oxygen therapy in selected acute illnesses. *J Intens Care Soc.* 2014;15(3):190–8.
- Abman SH, Collaco JM, Shepherd EG, Kesler M, Cuevas-Guaman M, Welty SE, Nelin LD. Interdisciplinary care of children with severe bronchopulmonary dysplasia. *J Pediatr.* 2017;181(12–28):e1.

3. Schmidt B. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. *JAMA*. 2003;289(9):1124.
4. Jeng S-F, Hsu C-H, Tsao P-N, Chou H-C, Lee W-T, Kao H-A, Hung H-Y, Chang J-H, Chiu N-C, Hsieh W-S. Bronchopulmonary dysplasia predicts adverse developmental and clinical outcomes in very-low-birthweight infants. *Dev Med Child Neurol*. 2008;50(1):51–7.
5. Laughon MM, Brian Smith P, Bose C. Prevention of bronchopulmonary dysplasia. *Semin Fetal Neonat Med*. 2009;14(6):374–82.
6. Kim GB. Pulmonary hypertension in infants with bronchopulmonary dysplasia. *Korean J Pediatr*. 2010;53(6):688.
7. O'Driscoll BR, Howard LS, Earis J, Mak V. BTS guideline for oxygen use in adults in healthcare and emergency settings. *Thorax*. 2017;72(1):iii1–90.
8. Vincent J-L, Taccone FS, He X. Harmful effects of hyperoxia in postcardiac arrest, sepsis, traumatic brain injury, or stroke: the importance of individualized oxygen therapy in critically ill patients. *Can Respir J Hindawi Ltd*. 2017;2017:1–7.
9. O'Reilly M, Thébaud B. Animal models of bronchopulmonary dysplasia. The term rat models. *Am J Physiol*. 2014;307(12):L948–58.
10. de Visser YP, Walther FJ, Laghmani EH, van der Laarse A, Wagenaar GTM. Apelin attenuates hyperoxic lung and heart injury in neonatal rats. *Am J Respir Crit Care Med*. 2010;182(10):1239–50.
11. Burri PH. Structural aspects of postnatal lung development—alveolar formation and growth. *Neonatology*. 2006;89(4):313–22.
12. Bhandari V. Hyperoxia-derived lung damage in preterm infants. *Semin Fetal Neonat Med*. 2010;15(4):223–9.
13. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A, Egido J. Animal models of cardiovascular diseases. *J Biomed Biotechnol*. 2011;2011:1–13.
14. Ambalavanan N, Morty RE. Searching for better animal models of BPD: a perspective. *Am J Physiol*. 2016;311(5):L924–7.
15. Nardiello C, Mižiková I, Morty RE. Looking ahead: where to next for animal models of bronchopulmonary dysplasia? *Cell Tissue Res*. 2016;367(3):457–68.
16. Taguchi L, Pinheiro NM, Olivo CR, Choqueta-Toledo A, Grecco SS, Lopes FD, Caperuto LC, Martins MA, Tiberio IF, Câmara NO, Lago JHG, Prado CM. A flavanone from *Baccharis retusa* (Asteraceae) prevents elastase-induced emphysema in mice by regulating NF- κ B, oxidative stress and metalloproteinases. *Respir Res*. 2015;16(1):79.
17. Schmitz T, Endesfelder S, Reinert M-C, Klinker F, Müller S, Bührer C, Liebetanz D. Adolescent hyperactivity and impaired coordination after neonatal hyperoxia. *Exp Neurol*. 2012;235(1):374–9.
18. Hershenson MB, Aghili S, Punjabi N, Hernandez C, Ray DW, Garland A, Glagov S, Solway J. Hyperoxia-induced airway hyperresponsiveness and remodeling in immature rats. *Am J Physiol*. 1992;262(3):L263–9.
19. Szarek JL, Ramsay HL, Andringa A, Miller ML. Time course of airway hyperresponsiveness and remodeling induced by hyperoxia in rats. *Am J Physiol*. 1995;269(2):L227–33.
20. Jankord R, Herman JP. Limbic regulation of hypothalamo-pituitary-adrenocortical function during acute and chronic stress. *Ann N Y Acad Sci*. 2008;1148(1):64–73.
21. Jiménez J, Richter J, Nagatomo T, Salaets T, Quarck R, Wagennar A, Wan H, Vanoirbeek J, Deprest J, Toelen J. Progressive vascular functional and structural damage in a bronchopulmonary dysplasia model in preterm rabbits exposed to hyperoxia. *Int J Mol Sci*. 2016;17(10):1776.
22. Choi CW, Kim BI, Mason SN, Potts-Kant EN, Brahmajothi MV, Auten RL. Intra-amniotic LPS amplifies hyperoxia-induced airway hyperreactivity in neonatal rats. *Pediatr Res*. 2013;74(1):11–8.
23. Gomes RFM, Shen X, Ramchandani R, Tepper RS, Bates JHT. Comparative respiratory system mechanics in rodents. *J Appl Physiol*. 2000;89(3):908–16.
24. Hong Z-Y, Eun SH, Park K, Choi WH, Lee JI, Lee EJ, Lee JM, Story MD, Cho J. Development of a small animal model to simulate clinical stereotactic body radiotherapy-induced central and peripheral lung injuries. *J Rad Res*. 2014;55(4):648–57.
25. Hartney JM, Robichaud A. Assessment of airway hyperresponsiveness in mouse models of allergic lung disease using detailed measurements of respiratory mechanics. *Mouse Models Allerg Dis*. 2013;1032:205–17.
26. Ni J, Dong Z, Han W, Kondrikov D, Su Y. The role of RhoA and cytoskeleton in myofibroblast transformation in hyperoxic lung fibrosis. *Free Radical Biol Med*. 2013;61:26–39.
27. Penke LRK, Huang SK, White ES, Peters-Golden M. Prostaglandin E2 inhibits α -smooth muscle actin transcription during myofibroblast differentiation via distinct mechanisms of modulation of serum response factor and myocardin-related transcription factor-A. *J Biol Chem*. 2014;289(24):17151–62.
28. Sakai H, Ingenito EP, Mora R, Abbay S, Cavalcante FSA, Lutchen KR, Suki B. Hysteresivity of the lung and tissue strip in the normal rat: effects of heterogeneities. *J Appl Physiol*. 2001;91(2):737–47.
29. Lutchen KR, Greenstein JL, Suki B. How inhomogeneities and airway walls affect frequency dependence and separation of airway and tissue properties. *J Appl Physiol*. 1996;80(5):1696–707.
30. Thorpe CW, Bates JHT. Effect of stochastic heterogeneity on lung impedance during acute bronchoconstriction: a model analysis. *J Appl Physiol*. 1997;82(5):1616–25.
31. Bates JHT, Allen GB. The estimation of lung mechanics parameters in the presence of pathology: a theoretical analysis. *Ann Biomed Eng*. 2006;34(3):384–92.
32. Allen G, Bates JHT. Dynamic mechanical consequences of deep inflation in mice depend on type and degree of lung injury. *J Appl Physiol*. 2004;96(1):293–300.
33. Hamakawa H, Bartolák-Suki E, Parameswaran H, Majumdar A, Lutchen KR, Suki B. Structure–function relations in an elastase-induced mouse model of emphysema. *Am J Respir Cell Mol Biol*. 2011;45(3):517–24.
34. Tolnai J, Szabari MV, Albu G, Maár BA, Parameswaran H, Bartolák-Suki E, Hantos Z. Functional and morphological assessment of early impairment of airway function in a rat model of emphysema. *J Appl Physiol*. 2012;112(11):1932–9.
35. Jagarapu J, Kelchtermans J, Rong M, Chen S, Hehre D, Hummler S, Faridi MH, Gupta V, Wu S. Efficacy of leukadherin-1 in the prevention of hyperoxia-induced lung injury in neonatal rats. *Am J Respir Cell Mol Biol*. 2015;53(6):793–801.
36. Alvira CM. Aberrant pulmonary vascular growth and remodeling in bronchopulmonary dysplasia. *Front Med*. 2016;3:21.
37. Wedgwood S, Warford C, Agvateesiri SC, Thai P, Berkelhamer SK, Perez M, Underwood MA, Steinhorn RH. Postnatal growth restriction augments oxygen-induced pulmonary hypertension in a neonatal rat model of bronchopulmonary dysplasia. *Pediatr Res*. 2016;80(6):894–902.
38. Baker CD, Abman SH, Mourani PM. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. *Pediatr Allerg Immunol Pulmonol*. 2014;27(1):8–16.
39. Baumann P, Fouzas S, Pramana I, Grass B, Niesse O, Bührer C, Spanaus K, Wellmann S. Plasma proendothelin-1 as an early marker of bronchopulmonary dysplasia. *Neonatology*. 2015;108(4):293–6.